Targeting JPX: A Protein with Potential as A Negative Regulator of Gene Expression

Target Name: JPX

NCBI ID: G554203

Content of Review Report on JPX Target / Biomarker

JPX

Other Name(s): LINC00183 | DCBALD06 | JPX transcript, XIST activator | ENOX | NCRNA00183

Targeting JPX: A Protein with Potential as A Negative Regulator of Gene Expression

JPX (LINC00183) is a protein that is expressed in various tissues of the human body, including the brain, heart, liver, and kidneys. It is a member of the homeobox gene family, which is a group of transcription factors that play a crucial role in the development and maintenance of tissues.

The homeobox gene family includes several proteins that are involved in the regulation of gene expression and cell biology. These proteins are characterized by the presence of a special domain called a homeobox gene signature, which is a unique combination of DNA-binding motifs.

JPX is a 21-kDa protein that is expressed in the brain, heart, liver, and kidneys. It is highly conserved, with a calculated identity of 97% at the amino acid level and a calculated molecular weight of 19.9 kDa.

JPX functions as a negative regulator of gene expression, which means that it works to prevent the translation of certain mRNAs into proteins. This is done by binding to specific DNA sequences, which then prevent the associated RNA polymerase from binding to the protein and starting the translation process.

JPX has been shown to play a role in the regulation of various biological processes, including cell growth, differentiation, and inflammation. It has also been shown to be involved in the development and progression of various diseases, including cancer and neurodegenerative disorders.

Due to its unique function and its role in several important biological processes, JPX has been identified as a potential drug target. Researchers are currently studying the potential mechanisms of action of JPX and developing potential therapeutic compounds that can target this protein.

Targeting JPX

One of the main strategies for targeting JPX is to develop small molecules that can inhibit its function as a negative regulator of gene expression. This can be done by binding to specific JPX DNA binding motifs and preventing the association of JPX with its DNA.

Another approach for targeting JPX is to use antibodies that recognize and label JPX protein and then use them to block its function. This can be done by using antibodies that specifically recognize JPX and then using them to block its function in cells.

Another potential strategy for targeting JPX is to use small molecules that can modulate its expression levels. This can be done by using small molecules that can bind to JPX and then modulate its levels in cells.

Antibodies against JPX have been developed and are being used in clinical trials to target its function as a negative regulator of gene expression. These antibodies are designed to recognize specific JPX DNA binding motifs and can be used to block its function in cells.

Conclusion

JPX is a protein that is expressed in various tissues of the human body and plays a crucial role in the regulation of gene expression and cell biology. It is a potential drug target due to its unique function and its role in several important biological processes. Researchers are currently studying the potential mechanisms of action of JPX and developing potential therapeutic compounds that can target this protein.

Protein Name: JPX Transcript, XIST Activator

The "JPX Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about JPX comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets